Filing Overview
Immix Biopharma, Inc. filed a Form 8-K dated June 7, 2023, reporting the results of its 2023 annual meeting of stockholders. A quorum was present, with 9,542,470 common shares represented in person or by proxy.
Business Context and Reporting Period
The filing concerns corporate governance and stockholder approvals rather than quarterly or annual financial results. The company is an emerging growth company, and its common stock trades on Nasdaq under the symbol IMMX.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
Annual Meeting Results
| Proposal | Result | Vote Summary |
|---|---|---|
| Election of directors | All seven nominees elected | Each nominee received between 7,457,001 and 7,600,072 votes for; withhold votes ranged from 22,447 to 165,518. Broker non-votes were approximately 1,919,951 to 1,919,952. |
| Ratification of KMJ Corbin & Company LLP | Approved | 9,497,865 for; 36,813 against; 7,792 abstentions; no broker non-votes. |
| Amended and Restated 2021 Omnibus Equity Incentive Plan | Approved | 7,315,768 for; 295,959 against; 10,792 abstentions; 1,919,951 broker non-votes. |
Material Changes, Outlook and Risks
All seven incumbent director terms expired at the meeting, and the seven nominees were elected to serve until the next annual meeting or until their successors are elected and qualified.
Stockholders approved the independent registered public accounting firm for the fiscal year ending December 31, 2023 and approved the amended equity incentive plan. The filing provides no management outlook, guidance, risk update, financing announcement, contingency, or unusual financial item.
The filing labels both the auditor ratification and equity incentive plan votes as “Proposal 2.” This appears to be a source-labeling inconsistency and should be verified against the definitive proxy statement filed April 25, 2023.
Investor Verification Checklist
- Verify the final proposal numbering and the terms of the amended equity incentive plan in the definitive proxy statement.
- Review the company’s latest periodic filing for financial condition, cash runway, debt, operating losses, and liquidity, none of which are reported in this 8-K.
- Confirm the identities and committee assignments of the seven elected directors.
- Assess the potential dilution and equity-compensation impact of the amended incentive plan.
- Confirm KMJ Corbin & Company LLP’s appointment and review any subsequent auditor or financial-reporting developments.